Search...
TEDA BIOMEDICAL released its interim results, with a loss attributable to shareholders of 6.4264 million yuan, an increase of 55.86% year-on-year
I'm PortAI, I can summarize articles.
According to the Zhitong Finance APP, TEDA BIOMEDICAL released its interim results for the six months ending June 30, 2025, with a group revenue of RMB 226 million, a year-on-year increase of 7.01%; the loss attributable to shareholders was RMB 6.4264 million, a year-on-year increase of 55.86%; the loss per share was 0.317 cents
According to the Zhitong Finance APP, TEDA BIOMEDICAL (08189) announced its interim results for the six months ending June 30, 2025, with a group revenue of RMB 226 million, an increase of 7.01% year-on-year; the loss attributable to shareholders was RMB 6.4264 million, an increase of 55.86% year-on-year; the loss per share was 0.317 cents
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments